The DOI matches its Crossref record; 241 of the 241 references it cites were found in a registry or an index.
Epigenetics of colorectal cancer: biomarker and therapeutic potential
Open accessAbstract
Colorectal cancer (CRC), a leading cause of cancer-related death worldwide, evolves as a result of the stepwise accumulation of a series of genetic and epigenetic alterations in the normal colonic epithelium, leading to the development of colorectal adenomas and invasive adenocarcinomas. Although genetic alterations have a major role in a subset of CRCs, the pathophysiological contribution of epigenetic aberrations in this malignancy has attracted considerable attention. Data from the past couple of decades has unequivocally illustrated that epigenetic marks are important molecular hallmarks of cancer, as they occur very early in disease pathogenesis, involve virtually all key cancer-associated pathways and, most importantly, can be exploited as clinically relevant disease biomarkers for diagnosis, prognostication and prediction of treatment response. In this Review, we summarize the current knowledge on the best-studied epigenetic modifications in CRC, including DNA methylation and histone modifications, as well as the role of non-coding RNAs as epigenetic regulators. We focus on the emerging potential for the bench-to-bedside translation of some of these epigenetic alterations into clinical practice and discuss the burgeoning evidence supporting the potential of emerging epigenetic therapies in CRC as we usher in the era of precision medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Additionally, ncRNA species such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) also have roles as epigenetic regulators in CRC and are implicated in many cancer-related pathways, including the Wnt/β-catenin, RAS/MAPK, p53, TGF-β, and PI3K/AKT signaling pathways [21].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Furthermore, DNA hypomethylation at regulatory and/or coding regions has been linked to the activation of proto-oncogenes [21].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In CRC, CIMP is intrinsically associated with hypermethylation of the MLH1 promoter and mutations in BRAF [21].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, an important limitation of the use of ncRNAs is the challenge of passing hydrated liposomal delivery vectors across hydrophobic membranes of tumor cells, underpinning the need for molecular modifications or the design of vehicles to aid specific delivery [21].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Numerous studies have demonstrated HDAC inhibitors to be effective in CRC cells when used in combination with chemotherapy drugs such as 5-FU, oxaliplatin, and irinotecan [21,66].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [21]
Experimental — accuracy not yet measured
7 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Yin, D., He, X., Zhang, E., Kong, R., De, W., & Zhang, Z. (2014) · Medical Oncology · doi:10.1007/s12032-014-0253-8 · Cited by 185
RetractedBray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Siegel, R. L., Miller, K. D., & Jemal, A. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21551 · Cited by 20,160
Ror2 signaling regulates Golgi structure and transport through IFT20 for tumor invasiveness
Nishita, M., Park, S.-Y., Nishio, T., Kamizaki, K., Wang, Z., Tamada, K., Takumi, T., Hashimoto, R., Otani, H., Pazour, G. J., et al. (2017) · Scientific Reports · doi:10.1038/s41598-016-0028-x · Cited by 15,947
A genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
The consensus molecular subtypes of colorectal cancer
Guinney, J., Dienstmann, R., Wang, X., de Reyniès, A., Schlicker, A., Soneson, C., Marisa, L., Roepman, P., Nyamundanda, G., Angelino, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3967 · Cited by 5,170
Non-coding RNAs in human disease
Esteller, M. (2011) · Nature Reviews Genetics · doi:10.1038/nrg3074 · Cited by 4,825
CpG Islands in vertebrate genomes
Gardiner-Garden, M., & Frommer, M. (1987) · Journal of Molecular Biology · doi:10.1016/0022-2836(87)90689-9 · Cited by 3,353
Cited by
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy
Li, Q., Geng, S., Luo, H., Wang, W., Mo, Y.-Q., Luo, Q., Wang, L., Song, G.-B., Sheng, J.-P., & Xu, B. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01953-7 · Cited by 546
Xie, M., Yu, T., Jing, X., Ma, L., Fan, Y., Yang, F., Ma, P., Jiang, H., Wu, X., Shu, Y., et al. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01208-3 · Cited by 429
Signaling pathways and targeted therapies for psoriasis
Guo, J., Zhang, H., Lin, W., Lu, L., Su, J., & Chen, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01655-6 · Cited by 427
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
Yang, J., Xu, J., Wang, W., Zhang, B., Yu, X., & Shi, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01480-x · Cited by 388
Non-coding RNAs and potential therapeutic targeting in cancer
Toden, S., Zumwalt, T. J., & Goel, A. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188491 · Cited by 327
Self-citation
Metadata
- Authors
- Jung, G., Hernández-Illán, E., Moreira, L., Balaguer, F., & Goel, A.
- Affiliations
- Hospital Clínic de Barcelona (ES)
- City Of Hope National Medical Center (US)
- Corresponding author
- Balaguer, Francesc
- Goel, Ajay
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2020-01-03
- Volume
- 17
- Issue
- 2
- Pages
- 111-130
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- PMC
- PMC7228650
- OpenAlex
- W2997492439
- Cited by
- 813
- References
- 241
- Citations by year
- 2026: 78 · 2025: 108 · 2024: 156 · 2023: 136 · 2022: 137 · 2021: 153 · 2020: 44
- FWCI
- 11.44
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Gastroenterology & Hepatology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA072851, R01CA184792, R01CA202797, U01CA187956, U01CA214254)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- colorectal cancer, epigenetics, DNA methylation, histone modifications, non-coding RNA, epigenetic biomarkers, prognostic factors, predictive biomarkers, epigenetic therapy, precision medicine, colorectal adenoma
- MeSH terms
- Adenocarcinoma, Adenoma, Humans, Prognosis, Biomarkers, Tumor, Colorectal Neoplasms, DNA Methylation, MicroRNAs, Histone Code, Epigenesis, Genetic, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Epigenetics of colorectal cancer: biomarker and therapeutic potential. https://app.cochat.ai/papers/10.1038/s41575-019-0230-y
- The paper
- Jung, G., Hernández-Illán, E., Moreira, L., Balaguer, F., & Goel, A. (2020). Epigenetics of colorectal cancer: biomarker and therapeutic potential. Nature Reviews Gastroenterology & Hepatology. https://doi.org/10.1038/s41575-019-0230-y
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.